{"id":18340,"date":"2023-01-06T15:44:46","date_gmt":"2023-01-06T15:44:46","guid":{"rendered":"https:\/\/by-tv.co.uk\/?p=18340"},"modified":"2023-01-06T15:50:23","modified_gmt":"2023-01-06T15:50:23","slug":"biontech-ile-ingilterede-arasinda-dev-ortaklik","status":"publish","type":"post","link":"https:\/\/by-tv.co.uk\/en\/biontech-ile-ingilterede-arasinda-dev-ortaklik\/","title":{"rendered":"BioNTech ile \u0130ngiltere&#8217;de aras\u0131nda dev ortakl\u0131k. Cambridge&#8217;de ara\u015ft\u0131rma merkezi kurulacak"},"content":{"rendered":"<p>BioNTech&#8217;ten yap\u0131lan a\u00e7\u0131klamada, \u0130ngiltere&#8217;de kanser tedavisi i\u00e7in bir ara\u015ft\u0131rma ve geli\u015ftirme merkezi kurulmas\u0131 i\u00e7in \u0130ngiltere Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 ile anla\u015f\u0131ld\u0131\u011f\u0131 belirtildi.<\/p>\n<blockquote class=\"twitter-tweet\">\n<p dir=\"ltr\" lang=\"en\">\ud83e\udd1d We&#8217;ve agreed a partnership with <a href=\"https:\/\/twitter.com\/BioNTech_Group?ref_src=twsrc%5Etfw\" target=\"_blank\" rel=\"noopener\">@BioNTech_Group<\/a> which means cancer patients will benefit from innovative research into potentially lifesaving vaccines and immunotherapy.<\/p>\n<p>Eligible patients could enter clinical trials for new treatments this autumn.<br \/>\n<a href=\"https:\/\/t.co\/uvUeJbR8X9\">https:\/\/t.co\/uvUeJbR8X9<\/a> <a href=\"https:\/\/t.co\/i3dADLzC7D\">pic.twitter.com\/i3dADLzC7D<\/a><\/p>\n<p>\u2014 Department of Health and Social Care (@DHSCgovuk) <a href=\"https:\/\/twitter.com\/DHSCgovuk\/status\/1611263925818998786?ref_src=twsrc%5Etfw\" target=\"_blank\" rel=\"noopener\">January 6, 2023<\/a><\/p><\/blockquote>\n<p><script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><br \/>\nA\u00e7\u0131klamada, 2030 y\u0131l\u0131na kadar mRNA kanser imm\u00fcnoterapileri ile 10 bin kadar kanser hastas\u0131n\u0131n klinik deneylerde tedavi edilmesinin ama\u00e7land\u0131\u011f\u0131 vurguland\u0131.<\/p>\n<p>2023&#8217;\u00fcn ikinci yar\u0131s\u0131nda ilk kanser hastas\u0131n\u0131n klinik deneylere dahil edilmesinin planland\u0131\u011f\u0131n\u0131n ifade edildi\u011fi a\u00e7\u0131klamada, BioNTech&#8217;in, \u00fclkenin Cambridge \u015fehrinde 70&#8217;ten fazla bilim insan\u0131n\u0131n istihdam edilece\u011fi bir AR-GE merkezi a\u00e7aca\u011f\u0131 bildirildi.<\/p><div id=\"briti-3046862775\" class=\"briti-icerik\" style=\"margin-top: 5px;margin-bottom: 5px;\"><a href=\"https:\/\/piaryum.com\/services\/\" aria-label=\"piaryum banner\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/by-tv.co.uk\/wp-content\/uploads\/2025\/12\/Gemini_Generated_Image_g5yqr1g5yqr1g5yq.jpg\" alt=\"\"  width=\"2064\" height=\"1152\"   \/><\/a><\/div>\n<h4>Cambridge&#8217;de ara\u015ft\u0131rma merkezi kurulacak<\/h4>\n<p>A\u00e7\u0131klamada g\u00f6r\u00fc\u015flerine yer verilen BioNTech \u00dcst Y\u00f6neticisi (CEO) ve Kurucu Orta\u011f\u0131 Prof. Dr. U\u011fur \u015eahin, \u0130ngiltere ile var\u0131lan anla\u015fman\u0131n Kovid-19 pandemisinden al\u0131nan derslerin bir sonucu oldu\u011funu belirterek, \u201c\u0130\u015f birli\u011fi, d\u00fcnya \u00e7ap\u0131nda toplu olarak y\u00fcz milyonlarca insan\u0131 etkileyen \u00e7e\u015fitli kanser t\u00fcrleri ve bula\u015f\u0131c\u0131 hastal\u0131klar\u0131n tedavisine odaklanacak\u201d ifadesini kulland\u0131.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-18344\" src=\"https:\/\/by-tv.co.uk\/wp-content\/uploads\/2023\/01\/biontech.jpg\" alt=\"\" width=\"1024\" height=\"768\" title=\"\"><\/p>\n<p><a href=\"https:\/\/investors.biontech.de\/news-releases\/news-release-details\/biontech-announces-strategic-partnership-uk-government-provide\" target=\"_blank\" rel=\"noopener\">Prof.\u015eahin<\/a> &#8220;Hedefimiz: 2030 sonuna kadar 10.000 hastaya klinik deneylerle veya onayl\u0131 tedavilerle ki\u015fiselle\u015ftirilmi\u015f kanser terapileri sa\u011flamak. &#8221; dedi.<\/p>\n<p>BioNTech, 23 Aral\u0131k 2022\u2019de yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, , Kovid-19 a\u015f\u0131s\u0131n\u0131 \u00fcretmek i\u00e7in kullan\u0131lan mRNA teknolojisiyle s\u0131tma a\u015f\u0131s\u0131n\u0131n klinik deneylerine ba\u015fland\u0131\u011f\u0131n\u0131 bildirmi\u015fti.<\/p>\n<p>Kaynak: <a href=\"https:\/\/www.dunya.com\/saglik\/biontech-ile-ingilterede-arasinda-dev-ortaklik-haberi-681068\" target=\"_blank\" rel=\"noopener\">1<\/a><\/p>\n<div id=\"briti-1720522472\" class=\"briti-icerikten-sonra_2\" style=\"margin-top: 25px;margin-bottom: 25px;\"><a href=\"https:\/\/wa.me\/message\/NDZLLIOQT4H3O1\" aria-label=\"bytv reklam banner\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/by-tv.co.uk\/wp-content\/uploads\/2025\/12\/bytv-reklam-banner.jpg\" alt=\"\"  width=\"2376\" height=\"1008\"   \/><\/a><\/div>","protected":false},"excerpt":{"rendered":"<p>BioNTech&#8217;ten yap\u0131lan a\u00e7\u0131klamada, \u0130ngiltere&#8217;de kanser tedavisi i\u00e7in bir ara\u015ft\u0131rma ve geli\u015ftirme merkezi kurulmas\u0131 i\u00e7in \u0130ngiltere Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 ile anla\u015f\u0131ld\u0131\u011f\u0131 belirtildi. \ud83e\udd1d We&#8217;ve agreed a partnership with @BioNTech_Group which means cancer patients will benefit from innovative research into potentially lifesaving vaccines and immunotherapy. Eligible patients could enter clinical trials for new treatments this autumn. https:\/\/t.co\/uvUeJbR8X9 pic.twitter.com\/i3dADLzC7D \u2014 Department of Health and Social Care (@DHSCgovuk) January 6, 2023 A\u00e7\u0131klamada, 2030 y\u0131l\u0131na kadar mRNA kanser imm\u00fcnoterapileri ile 10 bin kadar kanser hastas\u0131n\u0131n klinik deneylerde tedavi edilmesinin ama\u00e7land\u0131\u011f\u0131 vurguland\u0131. 2023&#8217;\u00fcn ikinci yar\u0131s\u0131nda ilk kanser hastas\u0131n\u0131n klinik deneylere dahil edilmesinin planland\u0131\u011f\u0131n\u0131n ifade edildi\u011fi a\u00e7\u0131klamada, BioNTech&#8217;in, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":14347,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-18340","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-genel"],"_links":{"self":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/18340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/comments?post=18340"}],"version-history":[{"count":0,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/18340\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media\/14347"}],"wp:attachment":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media?parent=18340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/categories?post=18340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/tags?post=18340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}